A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

Summary

This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.

Timeline

Start

2017-09-29

Primary completion

2020-07-08

Completion

2020-07-08

Outcome

Outcome not reported

Stopped (Business): “The Relamorelin program is being terminated solely based on a business decision.”

Publications

• Camilleri M, Jencks KJ. Pharmacologic treatments for gastroparesis. Pharmacol Rev. 2025 Mar;77(2):100019. doi: 10.1016/j.pharmr.2024.100019. Epub 2024 Nov 23.

Drugs

Indications